HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Q1 Consumer Health Earnings Preview: Lifted By Welcome Changes, Or Slowed By Surprises?

Executive Summary

An end to US COVID-19 PHE on 10 April doesn’t end inflationary pressure on prices for consumer packaged goods. OTC, supplements and personal care product firms could be reporting consumers during Q1 were going along with price increases, opting for less expensive options or buying less.

You may also be interested in...



US OTC Monograph Overhaul Like Makeover To Resemble Other FDA Drug Application Programs

In draft guidance on format and content for OMORs, CDER framed recommendations by same model it’s used for guidances on other drug applications, common technical document for registration developed by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use.

Prestige Spies Opportunity Within UK’s Eye Care Category For TheraTears

Prestige hopes that bringing its TheraTears brand to the UK it will meet a “growing demand for a consumer-friendly eye care range designed to deliver against real eye care needs with ingredients that really work.”

J&J Adds $6.9bn To Talc Settlement Proposal To Smooth Path To Kenvue Consumer Spinoff

Firm proposes larger funding agreement to settle North American talc claims, apparently pivoting from appealing to Supreme Court a January circuit court decision upholding bankruptcy court ruling that its LTL subsidiary isn’t “financially distressed” enough to file for Chapter protection.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel